Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

Fig. 3

Comparison of Kaplan-Meier curves of progression-free survival and cancer-specific survival of metastatic renal cell carcinoma patients with treatment-free intervals <1 year and with synchronous metastases (a–d) and metachronous metastases (e–f) between patients receiving immunotherapy (IT) and targeted therapy (TT) according to the Heng risk groups

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us